Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
Phase II, single arm trial, evaluating molecularly selected, immune-based combination therapy
in maintenance treatments for advanced cholangiocarcinoma, selecting patients on the
homologous recombination deficient (HRD) signature.